Zhaoke Ophthalmology Commences Commercialisation of its First Drug with Bimatoprost Timolol Eye Drop (晶贝莹?) Obtaining Marketing Authorization from the National Medical Products Administration
Zhaoke Ophthalmology’s Cyclosporine A (CsA) Ophthalmic Gel Passed the Onsite Regulatory and Clinical Trial Inspections by the NMPA, and the GMP Compliance Inspection by the Guangdong Medical Products Administration
Zhaoke Ophthalmology Won the “Best Small and Mid-Cap Company” Award at the “Embracing 2023: the Seventh Golden Hong Kong Stocks Annual Awards Ceremony”
